Home Patients & Families Professionals Screening Research About Us Contact
Professionals
Font Size:  a a a
General Information

Objective

To provide the health care professionals with current guidelines and recommendations for the management of prostate cancer in Saskatchewan.

Procedure

A prostate cancer symposium was held in Saskatchewan to discuss management update. There was multidisciplinary attendance by urologists, medical oncologists, radiation oncologists, GP oncologists, pathologists, nursing staff, pharmacists, and epidemiologist.

Nine presenters did a literature search to collect the most recent data. 

In addition, three guest speakers were invited: a radiation oncologist from Alberta discussed the Alberta guidelines, a urologist from Manitoba discussed the role of cryotherapy and HIFU (High Intensity Focused Ultrasound), and a medical oncologist from Ontario discussed the role of chemotherapy and bisphosphonates in the management of metastatic hormone-refractory prostate cancer.

The American Urological Association and the European Urological Association guidelines were also discussed.

The topics of “early diagnosis and screening” and follow-up guidelines were not discussed in detail but were touched upon in some presentations.  Therefore, the guidelines will be circulated to the oncologists and urologists for a consensus for the next update.  Feedback will be requested from other health care professionals dealing with prostate cancer patients, especially the family physicians and palliative care services. Their comments may be used for further update.

The consensus decisions in this guideline were obtained from the physicians attending the Update Symposium. These are 5/6 radiation oncologists in Regina including the regional leader, 4/6 radiation oncologists in Saskatoon including the regional leader, 4/6 medical oncologists in Regina, 3/6 medical oncologists in Saskatoon, the Provincial Leader of Medical Oncology, two GP oncologists (one from Regina and one from Saskatoon), seven urologists from across the province, one pathologist from each of Regina and Saskatoon, the Vice-President of Population Health, the Vice President of Care Services Clinical, as well as the three guest speakers.  In addition, there was very valuable contribution from the Provincial Manager of Pharmacy, oncology pharmacists, the provincial leaders of nursing and radiation therapy, other nursing and radiation therapy staff.

Background

Prostate cancer is the most common male cancer and the second leading cause of male cancer death in Saskatchewan.  Its incidence has risen because of the aging population and the introduction and increasing use of the prostatic specific antigen (PSA) test in the late 1980s to early 1990s.  In Saskatchewan, it is estimated that 890 new patients will be diagnosed with prostate cancer in 2008 and 230 will die of it.  The estimated 2008 age-adjusted incidence rate in Saskatchewan is 153/100,000 and the age-adjusted mortality rate is 35/100,000 (1),(2).

More

Next - Screening and Early Detection
ff